ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

04 Apr 2022 04:00:01 By Nasdaq GlobeNewswire

Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future

30 Mar 2022 09:12:04 By Nasdaq GlobeNewswire

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

24 Mar 2022 13:05:01 By Nasdaq GlobeNewswire

Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

21 Mar 2022 04:05:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Two Upcoming Investor Conferences

21 Mar 2022 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

20 Mar 2022 01:50:00 By Nasdaq GlobeNewswire

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

17 Mar 2022 04:00:02 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

02 Mar 2022 11:15:00 By Nasdaq GlobeNewswire

Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

22 Feb 2022 04:05:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

31 Jan 2022 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

25 Jan 2022 04:00:01 By Nasdaq GlobeNewswire

Athira Pharma Provides 2022 Pipeline Outlook

05 Jan 2022 04:00:01 By Nasdaq GlobeNewswire

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

10 Nov 2021 13:05:03 By Nasdaq GlobeNewswire

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

10 Nov 2021 08:50:00 By Nasdaq GlobeNewswire

Athira Pharma to Present at Upcoming Investor Conferences

08 Nov 2021 04:00:01 By Nasdaq GlobeNewswire

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

29 Oct 2021 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

22 Oct 2021 05:22:35 By Nasdaq GlobeNewswire

Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

21 Oct 2021 13:05:00 By Nasdaq GlobeNewswire

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

29 Sep 2021 05:05:41 By Nasdaq GlobeNewswire

Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit

23 Aug 2021 04:30:44 By Nasdaq GlobeNewswire